FR2649120B1 - NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD - Google Patents

NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Info

Publication number
FR2649120B1
FR2649120B1 FR8908838A FR8908838A FR2649120B1 FR 2649120 B1 FR2649120 B1 FR 2649120B1 FR 8908838 A FR8908838 A FR 8908838A FR 8908838 A FR8908838 A FR 8908838A FR 2649120 B1 FR2649120 B1 FR 2649120B1
Authority
FR
France
Prior art keywords
strain
proteins
mutants
strains
producing recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8908838A
Other languages
French (fr)
Other versions
FR2649120A1 (en
Inventor
Calmels Thierry
Durand Henri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cayla
Original Assignee
Cayla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayla filed Critical Cayla
Priority to FR8908838A priority Critical patent/FR2649120B1/en
Priority to EP90910778A priority patent/EP0433431A1/en
Priority to PCT/FR1990/000479 priority patent/WO1991000357A1/en
Publication of FR2649120A1 publication Critical patent/FR2649120A1/en
Application granted granted Critical
Publication of FR2649120B1 publication Critical patent/FR2649120B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2451Glucanases acting on alpha-1,6-glucosidic bonds
    • C12N9/2457Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01041Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR8908838A 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD Expired - Lifetime FR2649120B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
EP90910778A EP0433431A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process
PCT/FR1990/000479 WO1991000357A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Publications (2)

Publication Number Publication Date
FR2649120A1 FR2649120A1 (en) 1991-01-04
FR2649120B1 true FR2649120B1 (en) 1994-01-28

Family

ID=9383358

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8908838A Expired - Lifetime FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Country Status (3)

Country Link
EP (1) EP0433431A1 (en)
FR (1) FR2649120B1 (en)
WO (1) WO1991000357A1 (en)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0786257T3 (en) 1992-06-03 2003-10-06 Genentech Inc Glycolysis variants of tissue plasminogen activator with improved therapeutic properties
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
EP0848755B2 (en) 1995-09-08 2011-02-09 Genentech, Inc. Vegf-related protein
IL125073A0 (en) 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6030619A (en) 1997-08-27 2000-02-29 Chiron Corporation Molecular mimetics of meningococcal B epitopes
IL135704A (en) 1997-10-29 2008-04-13 Genentech Inc Method of diagnosing neoplastic cell growth by detection of the wnt-1 induced secreted polypeptide wisp-1
IL135607A0 (en) 1997-10-29 2001-05-20 Genentech Inc Wnt-1 inducible genes
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
JP2003524389A (en) 1998-12-16 2003-08-19 カイロン コーポレイション Human cyclin dependent kinase (hPNQALRE)
EP1820859B9 (en) 1998-12-22 2009-10-28 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
DE60043322D1 (en) 1999-06-15 2009-12-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids for their coding
JP2003527833A (en) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド Chromophores / phosphors derived from flower insects and their use
EP1669371A3 (en) 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
DK1897944T3 (en) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologous polypeptides and their therapeutic use
US7605246B2 (en) 2000-01-10 2009-10-20 Novartis Vaccines And Diagnostics, Inc. Genes differentially expressed in breast cancer
CN1425066B (en) 2000-01-13 2010-05-26 杰南技术公司 novel STRA6 polypeptide
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE60136281D1 (en) 2000-08-24 2008-12-04 Genentech Inc METHOD FOR INHIBITING IL-22-INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR20060125923A (en) 2001-06-20 2006-12-06 제넨테크, 인크. Methods for Diagnosing and Treating Tumors and Compositions for the Same
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
ES2386346T3 (en) 2001-08-29 2012-08-17 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
NZ573739A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
ATE439368T1 (en) 2001-12-19 2009-08-15 Univ Chicago RAPID-RIPE FLUORESCENT PROTEINS AND METHOD FOR USE THEREOF
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP2005528905A (en) 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
US20040138114A1 (en) 2002-07-08 2004-07-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
JP5401001B2 (en) 2002-09-11 2014-01-29 ジェネンテック, インコーポレイテッド Novel compositions and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc Nouvelles compositions et methodes de traitement du psoriasis
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006516094A (en) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド Compositions and methods for treatment of natural killer cell related diseases
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
NZ541480A (en) 2003-03-12 2008-03-28 Genentech Inc Use of Bv8 and/or EG-VEGF to promote hematopoiesis
CN102258464A (en) 2003-04-04 2011-11-30 健泰科生物技术公司 High concentration antibody and protein formulations
US7452966B2 (en) 2003-06-12 2008-11-18 Eli Lilly And Company GLP-1 analog fusion proteins
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
PT1736541E (en) 2004-03-29 2013-01-31 Galpharma Co Ltd Novel modified galectin 9 protein and use thereof
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CN103290084A (en) 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
EP1865940B1 (en) 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP1893229B1 (en) 2005-06-03 2011-10-19 Ambrx, Inc. Improved human interferon molecules and their uses
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
BRPI0712987A2 (en) 2006-06-21 2012-04-10 Musc Found For Res Dev h-factor-targeted disease treatment
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
JP5451390B2 (en) 2006-09-08 2014-03-26 アンブルックス,インコーポレイテッド Transcription of suppressor TRNA in vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
KR20090105913A (en) 2006-11-02 2009-10-07 다니엘 제이 카폰 Hybrid immunoglobulins with moving parts
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR102055873B1 (en) 2007-07-09 2019-12-13 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
KR101559595B1 (en) 2007-07-16 2015-10-12 제넨테크, 인크. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PL2176296T3 (en) 2007-07-16 2012-07-31 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 Use of interleukin-22 in treating fatty liver
ES2908934T3 (en) 2007-10-04 2022-05-04 Zymogenetics Inc B7 Family Member ZB7H6 and Related Compositions and Methods
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
MX338336B (en) 2007-11-20 2016-04-07 Ambrx Inc Modified insulin polypeptides and their uses.
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
ES2640533T3 (en) 2008-04-09 2017-11-03 Genentech, Inc. Compositions and novel methods for the treatment of diseases related to immunity
ES2963062T3 (en) 2008-07-23 2024-03-25 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
EA019653B1 (en) 2008-09-26 2014-05-30 Амбркс Инк. Modified animal erythropoietin polypeptides and their uses
TR201802361T4 (en) 2008-09-26 2018-03-21 Ambrx Inc Microorganisms and vaccines dependent on unnatural amino acid replication.
SI2393828T1 (en) 2009-02-03 2017-01-31 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
NZ595574A (en) 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
DK2440228T3 (en) 2009-06-08 2018-12-17 Amunix Operating Inc Glucose regulating polypeptides and methods for their preparation and use
MX2011013183A (en) 2009-06-08 2012-04-20 Amunix Operating Inc POLYPEPTIDES OF THE HORMONE OF GROWTH AND METHODS OF PREPARATION AND ITS USE.
RU2573896C2 (en) 2009-10-15 2016-01-27 Дженентек, Инк. Chimeric fibroblast growth factors with changed receptor specificity
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
MX2012005464A (en) 2009-11-12 2012-06-08 Genentech Inc A method of promoting dendritic spine density.
JP5856065B2 (en) 2009-11-30 2016-02-09 ジェネンテック, インコーポレイテッド Compositions and methods for tumor diagnosis and treatment
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CA2793544A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN103037887B (en) 2010-06-25 2017-11-10 国家医疗保健研究所 Methods and pharmaceutical compositions for treating respiratory infections
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 Application of interleukin-22 in curing virus hepatitis
CA2811403A1 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
DK2968495T3 (en) 2013-03-15 2019-10-14 Daniel J Capon HYBRID IMMUNOGLOBULIN CONTAINING A NON-PEPTID-BRO
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
AU2015229186B2 (en) 2014-03-14 2021-01-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
MY193457A (en) 2017-02-08 2022-10-14 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CN111094334A (en) 2017-07-19 2020-05-01 美国卫生与公众服务部 Antibodies and methods for diagnosis and treatment of hepatitis B virus infection
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
CN108676786B (en) * 2018-05-31 2021-02-23 大连民族大学 Culture medium for producing lipase by fermenting torticola terricola and culture method thereof
ES3036955T3 (en) 2020-04-15 2025-09-26 Genentech Inc Copper loss mitigation
KR20250071294A (en) 2022-08-22 2025-05-21 압데라 테라퓨틱스 인크. DLL3 binding molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (en) * 1978-10-18 1987-02-16 Sandoz Ag NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
FR2569723B1 (en) * 1984-08-31 1986-09-19 Centre Nat Rech Scient APPLICATION OF ANTIBIOTICS FROM THE PHLEOMYCIN FAMILY AS A SELECTION AGENT IN THE FIELD OF GENETIC ENGINEERING
EP0215594B2 (en) * 1985-08-29 2003-10-15 Genencor International, Inc. Heterologous polypeptide expressed in filamentous fungi, processes for their preparation, and vectors for their preparation
GB8610600D0 (en) * 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma

Also Published As

Publication number Publication date
FR2649120A1 (en) 1991-01-04
EP0433431A1 (en) 1991-06-26
WO1991000357A1 (en) 1991-01-10

Similar Documents

Publication Publication Date Title
FR2649120B1 (en) NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
FI103129B1 (en) Saccaharomyces cerevisiae strain and method for producing a protein heterologous to S. cerevisiae
FR2646437B1 (en) NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
FR2620650B1 (en) PROCESS FOR PRODUCING POLYURETHANE LENSES, AND LENS PRODUCED THEREBY
KR900013082A (en) PF1022 substance, its production method and anthelmintic composition containing the substance
JPS6437295A (en) Production of l-threonine by fermentation
DK459989D0 (en) YEAR PROCESS
FR2701489B1 (en) PROCESS FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION.
FR2661191B1 (en) PROCESS FOR PRODUCING L-LYSINE BY FERMANTATION AND MUTANT FOR IMPLEMENTING THE PROCESS.
FR2476085B1 (en) COMPOUNDS OBTAINED BY CULTURE OF MICROORGANISMS BELONGING TO THE BACILLUS STRAIN AND METHOD FOR OBTAINING THEM
BE899661A (en) PROCESS FOR INCREASING THE PRODUCTION OF ANTIBIOTICS BY GENETIC RECOMBINATION IN VIVO.
FR2637913B1 (en) PROCESS FOR PRODUCING POLYSACCHARIDES BY FERMENTATION OF A HYDROCARBON SOURCE USING MICROORGANISMS
EA199700310A1 (en) BIOLOGICAL METHOD OF OBTAINING COMPOUNDS OF DIPEPTID NATURE
SE9002668D0 (en) PROCESS FOR THE PREPARATION OF ACTIVE MASS OF IMPROVED QUALITY FROM ACTIVE MASS WASTES FORMED DURING THE PRODUCTION OF LEAD ACCUMULATORS
FR2626286B1 (en) PROCESS FOR PRODUCING L-THREONINE BY FERMENTATION
BE884889A (en) PROCESS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR OBTAINING SPECTINOMYCIN AND THE LIKE THEREOF AND PRODUCTS THEREOF
IT8621422A1 (en) PROCESS AND PLANT FOR THE CONTINUOUS PRODUCTION OF FRUCTOSE 1,6-DIPHOSPHATE BY USING IMMOBILIZED BEER'S YEAST
FR2630888B1 (en) PROCESS FOR INCREASING THE PRODUCTIVITY OF SOWS
FR2573429B1 (en) NOVEL THIENOPYRIDINE DERIVATIVES AND A PROCESS FOR THEIR PREPARATION
BE883552A (en) IMPROVEMENT IN THE METHOD FOR ADJUSTING THE WIDTH OF A GLASS RIBBON PRODUCED BY A FLEET GLASS PRODUCTION PROCESS
RU93058644A (en) METHOD FOR PRODUCING BACTERIAL CELLS, DISPUTES, METABOLISM PRODUCTS
FR2652079B1 (en) PROCESS FOR THE PREPARATION OF BRIDGE CLAYS AND BRIDGE CLAYS OBTAINED ACCORDING TO THIS PROCESS.
FR2540873B1 (en) NOVEL INTERMEDIATES FOR THE PRODUCTION OF 2- (2-AMINOTHIAZOL-4-YL) GLYOXYLIC ACID DERIVATIVES OR A SALT OF THE SAME AND THE PROCESS FOR PRODUCING THE INTERMEDIATES
FR2650825B1 (en) NOVEL PYRANONE, PROCESS FOR ITS PREPARATION, ITS APPLICATION TO THE PREPARATION OF A NEW PYRIDINONE AND ITS PREPARATION PROCESS
FR2550549B1 (en) NOVEL CLAVIN-PRODUCING STRAIN, PROCESS FOR PREPARING THE SAME, AND A MICROBIOLOGICAL PROCESS FOR THE PRODUCTION OF CLAVIN ALKALOIDS